Form 4: Olema Pharmaceuticals Executive Sells Shares to Cover Tax Obligations After Performance-Based Stock Vesting

An Olema Pharmaceuticals executive sold shares to cover tax obligations following the vesting of performance-based restricted stock units.

Summary

• An Olema Pharmaceuticals executive, Cyrus C. Harmon, sold shares of common stock to cover tax withholding obligations related to the vesting of performance restricted stock units (PRSUs).
• The PRSUs were granted on November 11, 2022, and vested in two tranches, with 35% vesting on November 20, 2023, and the remaining 65% vesting on December 9, 2024, after the Compensation Committee certified the achievement of performance criteria.
• The sales were not discretionary trades but were automatically executed to satisfy tax obligations.
• A total of 29,250 shares were acquired on December 9, 2024, as part of the vesting.
• Sales of 8,256 shares occurred on December 10, 2024, at a weighted average price of $9.37, with prices ranging from $8.89 to $9.70.
• Additional sales of 7,958 shares occurred on December 11, 2024, at a weighted average price of $8.66, with prices ranging from $8.22 to $9.21.
• A further 179 shares were sold on December 11, 2024, at a weighted average price of $9.39, with prices ranging from $9.31 to $9.74.
• The shares are held by Harmon Family Investors LLC, of which Cyrus C. Harmon is the manager.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. While the sale of shares might raise minor concerns, it is a standard practice and does not indicate any significant negative sentiment.

Positives

• The vesting of the PRSUs indicates that the company met certain performance criteria set by the Compensation Committee.
• The automatic sale of shares to cover tax obligations is a standard practice for equity compensation.

Negatives

• The sale of shares by an executive, even for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term downward pressure on the stock price.
• The market may interpret the sale as a lack of confidence in the company's future prospects, although this is not the case here.

Management Comments

• The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs.
• The sale occurred automatically to satisfy the tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Executive stock sales for tax purposes are a common occurrence in the pharmaceutical industry, particularly after vesting of performance-based equity awards. This is a standard practice and does not necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• The practice of selling shares to cover tax obligations upon vesting of equity awards is standard across the pharmaceutical and biotech industries.
• Many companies, such as Amgen, Gilead Sciences, and Regeneron, have similar executive compensation structures that include performance-based equity awards and subsequent tax-related sales.
• The weighted average sale prices are within the typical range for stock transactions of this nature.

Stakeholder Impact

• The sale of shares may have a minor, short-term impact on the stock price, but it is not expected to have a significant long-term effect on shareholders.
• The vesting of PRSUs indicates that the company met certain performance goals, which is a positive sign for stakeholders.

Key Dates

Keywords

Olema Pharmaceuticals, stock sale, performance restricted stock units, PRSU, executive compensation, tax withholding, vesting, Harmon Family Investors LLC